Gilead submits lymphoma candidate idelalisib for FDA approval

09/12/2013 | American City Business Journals

Gilead Sciences filed an application with the FDA for approval to market its oral drug idelalisib for treatment of patients with indolent non-Hodgkin lymphoma who don't respond to Rituxan and chemotherapy with an alkylating agent. A similar application is being prepared for Europe.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC